scholarly journals Combining Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory Disorders

2018 ◽  
Vol 16 (9) ◽  
pp. 1374-1384 ◽  
Author(s):  
Robert P. Hirten ◽  
Marietta Iacucci ◽  
Shailja Shah ◽  
Subrata Ghosh ◽  
Jean-Frederic Colombel
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Inflammatory Disorders ◽  
Immune Mediated ◽  
Inflammatory Bowel

scholarly journals Management of Acute Severe Ulcerative Colitis in a Pregnant Woman With COVID-19 Infection: A Case Report and Review of the Literature

2020 ◽  
Vol 26 (7) ◽  
pp. 971-973 ◽  
Author(s):  
Melissa H Rosen ◽  
Jordan Axelrad ◽  
David Hudesman ◽  
David T Rubin ◽  
Shannon Chang
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
First Trimester ◽  
Review Of The Literature ◽  
Severe Ulcerative Colitis ◽  
Immune Mediated ◽  
First Trimester Of Pregnancy ◽  
Inflammatory Bowel ◽  
High Level

Abstract First detected in Wuhan, China, the novel 2019 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped RNA beta-coronavirus responsible for an unprecedented, worldwide pandemic caused by COVID-19. Optimal management of immunosuppression in inflammatory bowel disease (IBD) patients with COVID-19 infection currently is based on expert opinion, given the novelty of the infection and the corresponding lack of high-level evidence in patients with immune-mediated conditions. There are limited data regarding IBD patients with COVID-19 and no data regarding early pregnancy in the era of COVID-19. This article describes a patient with acute severe ulcerative colitis (UC) during her first trimester of pregnancy who also has COVID-19. The case presentation is followed by a review of the literature to date on COVID-19 in regard to inflammatory bowel disease and pregnancy, respectively.

scholarly journals Sulfasalazine-Induced Pancytopenia in Ulcerative Colitis

2016 ◽  
Vol 6 (3) ◽  
pp. 164-165
Author(s):  
NS Neki ◽  
Ankur Jain
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Adverse Effects ◽  
Bowel Disease ◽  
Modifying Agent ◽  
Immune Mediated ◽  
Established Disease ◽  
Inflammatory Bowel ◽  
Disease Modifying

Sulfasalazine is a well-established disease-modifying agent. It is commonly used in the treatment of rheumatic disorders and inflammatory bowel disease. The most frequently reported adverse effects are gastrointestinal effects, headache, dizziness and rash; myelosuppression can also occur. Patients treated with sulfasalazine can develop thrombocytopenia which is immune mediated. We report a case of ulcerative colitis that was on sulfasalazine subsequently developing thrombocytopenia.J Enam Med Col 2016; 6(3): 164-165

Lactobacillus casei LH23 modulates the immune response and ameliorates DSS-induced colitis via suppressing JNK/p-38 signal pathways and enhancing histone H3K9 acetylation

2020 ◽  
Vol 11 (6) ◽  
pp. 5473-5485
Author(s):  
Meiling Liu ◽  
Jinhua Ding ◽  
Hongmin Zhang ◽  
Jing Shen ◽  
Yunpeng Hao ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Immune Response ◽  
Bowel Disease ◽  
Lactobacillus Casei ◽  
Signal Pathways ◽  
Inflammatory Disorders ◽  
Inflammatory Bowel ◽  
H3k9 Acetylation

Probiotics are thought to have immunomodulatory functions, improve inflammatory disorders and treat inflammatory bowel disease (IBD).

Ω-3 Polyunsaturated Fatty Acids and Immune-Mediated Diseases: Inflammatory Bowel Disease and Rheumatoid Arthritis

2009 ◽  
Vol 15 (36) ◽  
pp. 4135-4148 ◽  
Author(s):  
C. Ruggiero ◽  
F. Lattanzio ◽  
F. Lauretani ◽  
B. Gasperini ◽  
C. Andres-Lacueva ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Inflammatory Bowel Disease ◽  
Fatty Acids ◽  
Polyunsaturated Fatty Acids ◽  
Bowel Disease ◽  
Immune Mediated ◽  
Inflammatory Bowel

scholarly journals Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise

2021 ◽  
Author(s):  
Silvio Danese ◽  
Laurent Peyrin-Biroulet
Keyword(s):  
Inflammatory Bowel Disease ◽  
Tyrosine Kinase ◽  
Bowel Disease ◽  
Inflammatory Diseases ◽  
Janus Kinase ◽  
Type I ◽  
Tyrosine Kinase 2 ◽  
Immune Mediated ◽  
Inflammatory Bowel

Abstract Conventional systemic and biologic agents are the mainstay of inflammatory bowel disease (IBD) management; however, many of these agents are associated with loss of clinical response, highlighting the need for effective, novel targeted therapies. Janus kinase (JAK) 1-3 and tyrosine kinase 2 (TYK2) mediate signal transduction events downstream of multiple cytokine receptors that regulate targeted gene transcription, including the interleukin-12, interleukin-23, and type I interferon receptors for TYK2. This review summarizes the role of TYK2 signaling in IBD pathogenesis, the differential selectivity of TYK2 inhibitors, and the potential clinical implications of TYK2 inhibition in IBD. A PubMed literature review was conducted to identify studies of JAK1-3 and TYK2 inhibitors in IBD and other immune-mediated inflammatory diseases. Key efficacy and safety information was extracted and summarized. Pan-JAK inhibitors provide inconsistent efficacy in patients with IBD and are associated with toxicities resulting from a lack of selectivity at therapeutic dosages. Selective inhibition of TYK2 signaling via an allosteric mechanism, with an agent that binds to the regulatory (pseudokinase) domain, may reduce potential toxicities typically associated with JAK1-3 inhibitors. Deucravacitinib, a novel, oral, selective TYK2 inhibitor, and brepocitinib and PF-06826647, TYK2 inhibitors that bind to the active site in the catalytic domain, are in development for IBD and other immune-mediated inflammatory diseases. Allosteric TYK2 inhibition is more selective than JAK1-3 inhibition and has the potential to limit toxicities typically associated with JAK1-3 inhibitors. Future studies will be important in establishing the role of selective, allosteric TYK2 inhibition in the management of IBD.

scholarly journals Non-neoplastic colorectal disease biopsies: evaluation and differential diagnosis

2020 ◽  
Vol 73 (12) ◽  
pp. 783-792
Author(s):  
Michelle Moore ◽  
Roger M Feakins ◽  
Gregory Y Lauwers
Keyword(s):  
Inflammatory Bowel Disease ◽  
Differential Diagnosis ◽  
Bowel Disease ◽  
Host Response ◽  
Histological Diagnosis ◽  
Colorectal Disease ◽  
Pattern Of Injury ◽  
Immune Mediated ◽  
Methodical Approach ◽  
Inflammatory Bowel

A wide variety of non-neoplastic conditions may be encountered on colorectal biopsy encompassing idiopathic, infectious, vascular and immune-mediated aetiologies. Although interpretation of such biopsies may be challenging, appreciation of the dominant pattern of injury and subsequent host response may allow for a more focused histological diagnosis in the correct clinical and endoscopic setting. This article aims to provide a systematic, methodical approach to the assessment of such biopsies, concentrating mainly on diagnoses other than inflammatory bowel disease.

Sign in / Sign up

Export Citation Format

Share Document